Nexthera Capital LP purchased a new position in Kalvista Pharmaceuticals Inc (NASDAQ:KALV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 180,794 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,763,000.
Other large investors have also recently modified their holdings of the company. Deutsche Bank AG boosted its stake in shares of Kalvista Pharmaceuticals by 1,679,980.0% in the fourth quarter. Deutsche Bank AG now owns 84,004 shares of the specialty pharmaceutical company’s stock worth $819,000 after acquiring an additional 83,999 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter worth approximately $865,000. Goldman Sachs Group Inc. acquired a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter worth approximately $151,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the fourth quarter worth approximately $202,000. 60.15% of the stock is currently owned by hedge funds and other institutional investors.
Separately, ValuEngine raised Kalvista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, December 14th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.05). The company had revenue of $1.13 million for the quarter. Kalvista Pharmaceuticals had a negative return on equity of 70.20% and a negative net margin of 1,379.58%.
TRADEMARK VIOLATION WARNING: This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2018/03/13/nexthera-capital-lp-invests-1-76-million-in-kalvista-pharmaceuticals-inc-kalv.html.
Kalvista Pharmaceuticals Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kalvista Pharmaceuticals Inc (NASDAQ:KALV).
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.